Novocure Ltd
NASDAQ:NVCR
Novocure Ltd
Revenue
Novocure Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novocure Ltd
NASDAQ:NVCR
|
Revenue
$621.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
43%
|
|
Novocure Ltd
Revenue Breakdown
Breakdown by Geography
Novocure Ltd
|
Total Revenue:
605.2m
USD
|
|
United States:
391.8m
USD
|
|
International Markets - Total:
196m
USD
|
|
Germany:
65.3m
USD
|
Breakdown by Segments
Novocure Ltd
Novocure Ltd
Glance View
Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.
See Also
What is Novocure Ltd's Revenue?
Revenue
621.7m
USD
Based on the financial report for Mar 31, 2025, Novocure Ltd's Revenue amounts to 621.7m USD.
What is Novocure Ltd's Revenue growth rate?
Revenue CAGR 10Y
43%
Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Novocure Ltd have been 5% over the past three years , 10% over the past five years , and 43% over the past ten years .
You don't have any saved screeners yet